Cencora, Inc. (COR) Stock

About Cencora, Inc.

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

Cencora, Inc. is led by CEO Robert Mauch, employs 47,000 people, headquartered in Conshohocken, US, publicly traded since 1995.

Cencora, Inc. (COR) stock trades at $318.61 with a market capitalization of $61.99B. The stock is valued at a price-to-earnings (P/E) ratio of 32.38, price-to-book of 33.25, price-to-sales of 0.15. Over the past 52 weeks the stock has ranged between $244.82 and $377.54, and currently trades 15.6% below its 52-week high. It pays a dividend yielding 0.91%.

On profitability, Cencora, Inc. generates a return on equity (ROE) of 103.05% — well above the market average, a sign of a high-quality business, return on capital employed of 208.82%, an operating margin of 1.14%, a net profit margin of 0.78%.

In its most recent fiscal year, Cencora, Inc. reported annual revenue of $321.3B, net profit of $1.6B, revenue has compounded at 11.1% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 3.65 — a leveraged balance sheet worth monitoring, a current ratio of 0.90, total assets of $76.6B, $4.4B in cash and equivalents.

COR has an average daily trading volume of 1,808,249 shares, a beta of 0.59 (less volatile than the overall market).

Official website: www.cencora.com